Santeri, Seppälä
Peter, Andersen Andreas
Kristiina, Nyyssönen
Jesper, Eugen-Olsen
Harri, Hyppölä
Article History
Received: 17 June 2021
Accepted: 21 November 2021
First Online: 29 November 2021
Declarations
:
: The study was a prospective study where no additional blood samples were taken and the study did not affect patient treatment at all. We consulted Science Service Center of the Kuopio University Hospital about the ethical aspects of this survey. As this study did not have effect on patient treatment and it could be regarded as a quality assurance study, the study approval could be asked from local decision maker, which each hospital district in Finland has its own. Our study was approved by South Savo social- and healthcare authority, which is an institutional Finnish hospital District (Study approval number 684/13.02.03/2019). Consent from patients was not required and that was approved in the study approval. All processing of personal data followed national guidelines.
: Not applicable.
: JEO is a co-founder, shareholder and CSO of ViroGates A/S. JEO named inventors on patents on suPAR. The patents are owned by Copenhagen University Hospital Hvidovre, Denmark and licensed to ViroGates A/S. APA is part-time statistician with ViroGates. HH has received a lecture fee from ViroGates A/S. All other authors declare no financial relationships with any organization that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.